Singapore, April 16 -- Nikon CeLL innovation (NCLi), a subsidiary of Japan-based Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc., a leading stem cell technology company in the US.

This agreement provides the Japanese biopharma industry with an end-to-end solution for development and manufacturing of human mesenchymal stem cells (MSC) and extracellular vesicle (EV) therapeutics.

Drug developers can leverage RoosterBio's technology platform to accelerate the development of their advanced therapies with NCLi, and then seamlessly transition to clinical manufacturing within NCLi'sGood Gene, Cellular, and Tissue-based Products Manufacturing Practice (GCTP)/ Good Manufacturing Practice (GMP) facility de...